rAAV9 combined with renal vein injection is optimal for kidney-targeted gene delivery: conclusion of a comparative study
Open Access
- 1 May 2014
- journal article
- research article
- Published by Springer Nature in Gene Therapy
- Vol. 21 (6) , 618-628
Abstract
Effective gene therapy strategies for the treatment of kidney disorders remain elusive. We report an optimized kidney-targeted gene delivery strategy using recombinant adeno-associated virus (rAAV) administered via retrograde renal vein injection in mice. Renal vein injection of rAAV consistently resulted in superior kidney transduction compared with tail vein injection using as little as half the tail vein dose. We compared rAAV5, 6, 8 and 9, containing either green fluorescent protein (GFP) or luciferase reporter genes driven by the Cytomegalovirus promoter. We demonstrated that although rAAV6 and 8 injected via renal vein transduced the kidney, transgene expression was mainly restricted to the medulla. Transgene expression was systematically low after rAAV5 injection, attributed to T-cell immune response, which could be overcome by transient immunosuppression. However, rAAV9 was the only serotype that permitted high-transduction efficiency of both the cortex and medulla. Moreover, both the glomeruli and tubules were targeted, with a higher efficiency within the glomeruli. To improve the specificity of kidney-targeted gene delivery with rAAV9, we used the parathyroid hormone receptor ‘kidney-specific’ promoter. We obtained a more efficient transgene expression within the kidney, and a significant reduction in other tissues. Our work represents the first comprehensive and clinically relevant study for kidney gene delivery.Keywords
This publication has 58 references indexed in Scilit:
- Comparison of the transduction efficiency of tyrosine‐mutant adeno‐associated virus serotype vectors in kidneyClinical and Experimental Pharmacology and Physiology, 2012
- Pharmacological Modulation of Humoral Immunity in a Nonhuman Primate Model of AAV Gene Transfer for Hemophilia BMolecular Therapy, 2012
- Successful attenuation of humoral immunity to viral capsid and transgenic protein following AAV-mediated gene transfer with a non-depleting CD4 antibody and cyclosporineGene Therapy, 2011
- Terminal N-Linked Galactose Is the Primary Receptor for Adeno-associated Virus 9Journal of Biological Chemistry, 2011
- Robust cardiomyocyte-specific gene expression following systemic injection of AAV: in vivo gene delivery follows a Poisson distributionGene Therapy, 2010
- A Single Intravenous Injection of Adeno-associated Virus Serotype-9 Leads to Whole Body Skeletal Muscle Transduction in DogsMolecular Therapy, 2008
- Gene Therapy Using Adeno-Associated Virus VectorsClinical Microbiology Reviews, 2008
- Safety and Efficacy of Gene Transfer for Leber's Congenital AmaurosisNew England Journal of Medicine, 2008
- Effect of Gene Therapy on Visual Function in Leber's Congenital AmaurosisNew England Journal of Medicine, 2008
- Induction of Robust Immune Responses against Human Immunodeficiency Virus Is Supported by the Inherent Tropism of Adeno-Associated Virus Type 5 forDendritic CellsJournal of Virology, 2006